文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

美国骨科手术器械关键性试验:双臂非劣效性设计占主导

Pivotal trials of orthopedic surgical devices in the United States: predominance of two-arm non-inferiority designs.
PubMed 文献 · Trials · 2017-07-24

该研究检索2000至2016年美国FDA骨科与康复器械专家组的会议材料,分析38个议题中23项器械关键性临床试验的设计与解读争议。结果显示20项(87.0%)为随机对照试验,其中13项(65.0%)为非劣效性试验、7项(35.0%)为优效性试验,且所有随机对照试验均为双臂试验。专家组最常辩论的问题与非劣效性试验的设计和解读有关。

要点

  • 2000至2016年FDA专家组审议38个议题,其中23项包含器械审批临床数据。
  • 23项关键性试验中20项(87.0%)为随机对照试验,13项(65.0%)为非劣效性、7项(35.0%)为优效性。
  • 所有随机对照试验均为双臂试验,专家组最常辩论非劣效性试验的设计与解读。

核心结论

  • FDA审议的骨科器械类型广泛,双臂非劣效性试验作为关键性研究占主导,表明其设计与解读的细微差别具有商业重要性。

研究设计与样本

  • 研究识别2000至2016年美国FDA骨科与康复器械专家组的会议,从FDA电子档案收集会议材料,记录器械类型、后续批准与召回、关键性临床试验设计及专家组审议中辩论的试验解读问题。
  • 专家组在35天内召开29次单独会议,审议38个不同议题;其中23个议题包含为审批器械提交的临床数据,2个议题被排除。
  • 23项器械中,5项为生物制剂、3项为髋关节置换、3项为椎间盘置换、2项为黏性补充剂、3项为棘突间装置、7项为其他器械。
  • 23项关键性试验中,20项(87.0%)为随机对照试验,包括13项(65.0%)非劣效性试验和7项(35.0%)优效性试验,所有随机对照试验均为双臂试验。

主要发现

  • 专家组审议的23项器械关键性试验中,随机对照试验占20项(87.0%),其中非劣效性试验13项(65.0%)、优效性试验7项(35.0%),所有随机对照试验均为双臂试验。
  • 专家组会议上最常辩论的问题与非劣效性试验的设计和解读有关。

关键数值与推荐

  • 23项关键性试验中,20项(87.0%)为随机对照试验,13项(65.0%)为非劣效性试验,7项(35.0%)为优效性试验,所有随机对照试验均为双臂试验。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The United States Food and Drug Administration (FDA) reviews class III orthopedic devices submitted for premarket approval with pivotal clinical trials. The purpose of this study was to determine the types of orthopedic devices reviewed, the design of their pivotal clinical trials, and the subjective factors affecting the interpretation of clinical trial data. METHODS: Meetings of the FDA Orthopaedic and Rehabilitation Devices Panel were identified from 2000-2016. Meeting materials were collected from FDA electronic archives and notes were made regarding the device-type and subsequent approval and recall, the design of pivotal clinical trials, and issues of trial interpretation debated during panel deliberations. RESULTS: The panel was convened on 29 separate occasions over the course of 35 days to deliberate 38 distinct topics. Of these, 23 topics included clinical data submitted for approval of a device, and two topics were excluded. Of the 23 devices, five were biologic, three were hip arthroplasty, three were disc arthroplasty, two were viscosupplementation, three were interspinous process devices, and seven were other devices. Of the 23 pivotal trials, 20 (87.0%) were randomized controlled trials (RCTs), consisting of 13 (65.0%) non-inferiority trials and 7 (35.0%) superiority trials, and all RCTs were two-arm trials. At panel, the most commonly debated issues were related to the design and interpretation of non-inferiority trials. CONCLUSIONS: A broad array of device types is reviewed by the FDA. The predominance of two-arm non-inferiority trials as pivotal studies indicates that the nuances of their design and interpretation are commercially important.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Golish SR. Pivotal trials of orthopedic surgical devices in the United States: predominance of two-arm non-inferiority designs. Trials. 2017. PMID: 28738891. doi:10.1186/s13063-017-2032-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。